Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pluri Inc PLUR

Healthcare Biotechnology

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PLUR)

15 Biggest Mid-Day Losers For Friday

Benzinga.com January 20, 2017

Mid-Day Market Update: Crude Oil Up 2.8%; Bristol-Myers Squibb Shares Slide After Opdivo Decision

Benzinga.com January 20, 2017

Mid-Morning Market Update: Markets Open Higher; General Electric Revenue Misses Views

Benzinga.com January 20, 2017

Pluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000

GlobeNewswire January 20, 2017

Pluristem Announces Bought Deal Offering

GlobeNewswire January 19, 2017

Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval

GlobeNewswire January 17, 2017

Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

GlobeNewswire January 12, 2017

Pluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA

GlobeNewswire January 10, 2017

Pluristem and New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD

GlobeNewswire December 27, 2016

Pluristem and Innovative Medical Management Co., Ltd. Mutually Agree to Extend the Time to Execute the Definitive Investment Agreements Due to New Chinese Monetary Policy

GlobeNewswire December 23, 2016

Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan

GlobeNewswire December 20, 2016

United States Congress Passes Bill that Represents a Major Opportunity for Regenerative Therapies

GlobeNewswire December 13, 2016

Pluristem’s PLX-R18 Advances into Second Cohort of Dose Selection Study for Treatment of Acute Radiation Syndrome

GlobeNewswire December 6, 2016

Pluristem Reports First Quarter Fiscal 2017 Corporate and Financial Highlights

GlobeNewswire November 15, 2016

Pluristem’s $30 Million Equity Funding Approved by Innovative Medical Management Co.’s Shareholders

GlobeNewswire November 10, 2016

Pluristem Continues to Strengthen its Position in China and Receives Key Cell Therapy Patent

GlobeNewswire November 7, 2016

Pluristem’s Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency

GlobeNewswire November 1, 2016

Pluristem Signs Term Sheet for $30 Million Equity Investment Agreement with a Leading Institutional Life Sciences Fund

GlobeNewswire October 25, 2016

Pluristem CEO Zami Aberman Re-Elected to Alliance for Regenerative Medicine’s Board of Directors

GlobeNewswire October 13, 2016

Pluristem Therapeutics, Inc. - "Biotech Nation"

Accesswire September 22, 2016